Introduction Quantification of amyloid plaques (A), neurofibrillary tangles (T2), and neurodegeneration (N) using PET and MRI is critical for Alzheimer’s disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing time, tracer variability handling, and multimodal integration. Methods We developed petBrain, a novel end-to-end processing pipeline for amyloid-PET, tau-PET, and structural MRI. It leverages deep learning-based segmentation, standardized biomarker quantification (Centiloid, CenTauR, HAVAs), and simultaneous estimation of A, T2, and N biomarkers. It is implemented in a web-based format, requiring no local computational infrastructure and software usage knowledge. Results petBrain provides reliable, rapid quantification with results comparable to existing pipelines for A and T2, showing strong concordance with data processed in ADNI databases. The staging and quantification of A/T2/N by petBrain demonstrated good agreements with CSF/plasma biomarkers, clinical status and cognitive performance. Discussion petBrain represents a powerful open platform for standardized AD biomarker analysis, facilitating clinical research applications.

The lifespan tree of brain anatomy improves multiclass differential diagnosis of neurodegenerative diseases by modeling brain volume changes over time. It outperforms SVM, provides interpretable dise...

Using brain charts that map structural changes in the brain across the human lifespan, Planche et al. estimate the neurodegenerative trajectories of the th

npj Parkinson's Disease - Additive effect of distant Lewy bodies and tau seeds injections on nigral degeneration in macaques

Click on the article title to read more.

Discover how cognitive profiles refine Alzheimer’s blood test results. Find out more.

npj Parkinson's Disease - Additive effect of distant Lewy bodies and tau seeds injections on nigral degeneration in macaques

Vincent Planche, neurologue bordelais, également enseignant et chercheur, travaille sur la maladie d’Alzheimer depuis 2017. Il vient notamment d’être récompensé par la Fondation de France pour ses

Vincent Planche, neurologue bordelais, également enseignant et chercheur, travaille sur la maladie d’Alzheimer depuis 2017. Il vient notamment d’être récompensé par la Fondation de France pour ses tra...

This cohort study investigates if the clinical phenotype of patients without dementia is associated with blood phosphorylated tau 217 interpretation.

Lecanemab, a monoclonal antibody targeting β-amyloid protofibrils, has shown promising results in a Phase III clinical trial for the treatment of earl…

Subscription and open access journals from Sage, the world's leading independent academic publisher.

Cognitive screening instruments are used daily in clinics devoted to the assessment of cognitive disorders and also in general neurology clinics where patients with complaints of memory disorder may b...

Anti-amyloid treatments for early symptomatic Alzheimer disease have greatly increased the need for biomarker confirmation of amyloid pathology and blood biomarker tests offer an accessible and scalab...